ABCG2 and myeloproliferative disorder: Considering the clinical importance in PV, we addressed the ruxolitinib transport by ABCG2 in RBCs from 12 MPN patients with a range of ABCG2+ RBCs of 20–85% (Figure 3A) and from ABCG2null individuals as the control.